Senologie - Zeitschrift für Mammadiagnostik und -therapie 2024; 21(02): e2-e3
DOI: 10.1055/s-0044-1786072
Abstracts

Radar reflectors for marking of target lymph nodes in patients receiving neoadjuvant chemotherapy for breast cancer – a subgroup analysis of the prospective AXSANA (EUBREAST-03) trial

Authors

  • M. Banys-Paluchowski

    1   Universitätsklinikum Schleswig-Holstein Campus Lübeck, Lübeck, Deutschland

  • T. Basali

    2   Department of Gynecology and Obstetrics, Klinikum Esslingen, Esslingen, Deutschland

  • S. Hartmann

    3   Department of Gynecology and Obstetrics, University Hospital Rostock, Rostock, Deutschland

  • J. de Boniface

    4   Department of Molecular Medicine and Surgery, Karolinska Institutet; Department of Surgery, Capio St. Göran’s Hospital, Stockholm, Schweden

  • O. D. Gentilini

    5   Breast Unit, IRCCS San Raffaele Scientific Institute, Milan, Italien
    6   Università Vita-Salute San Raffaele, Milan, Italien

  • E. Stickeler

    7   Department of Gynecology and Obstetrics, University Hospital Aachen, Aachen, Deutschland

  • M. Untch

    8   Breast Cancer Center, Clinic for Gynecology and Obstetrics, Helios Klinikum Berlin-Buch, Berlin, Deutschland

  • F. Ruf

    1   Universitätsklinikum Schleswig-Holstein Campus Lübeck, Lübeck, Deutschland

  • S. Fröhlich

    3   Department of Gynecology and Obstetrics, University Hospital Rostock, Rostock, Deutschland

  • M. L. Gasparri

    9   Department of Gynecology and Obstetrics, Ospedale Regionale di Lugano EOC; Centro di Senologia della Svizzera Italiana (CSSI), Ente Ospedaliero Cantonale; Faculty of Biomedical Sciences, Università della Svizzera Italiana (USI), Lugano, Deutschland

  • M. Thill

    10   Department of Gynecology and Gynecological Oncology, AGAPLESION Markus Krankenhaus, Frankfurt am Main, Deutschland

  • M. P. Lux

    11   Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, Frauenklinik St. Josefs-Krankenhaus, Salzkotten, St. Vincenz Kliniken, Paderborn, Deutschland

  • F. Peintinger

    12   Universitätsklinik für Frauenheilkunde und Geburtshilfe, Graz & Institut für Pathologie, Med. Univ Graz, Graz, Österreich

  • G. Karadeniz Cakmak

    13   Zonguldak BEUN The School of Medicine, General Surgery Department, Breast and Endocrine Unit, Kozlu/Zonguldak, Türkei

  • I. T. Rubio

    14   Breast Surgical Unit, Clínica Universidad de Navarra, Madrid, Spanien

  • M. Kontos

    15   1st Department of Surgery, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Griechenland

  • R. Di Micco

    5   Breast Unit, IRCCS San Raffaele Scientific Institute, Milan, Italien

  • D. Murawa

    16   Department of General Surgery and Surgical Oncology, Collegium Medicum, University of Zielona Góra, Zielona Góra, Polen

  • E. Schlichting

    17   Oslo University Hospital, Oslo, Norwegen

  • B. Aktas Sezen

    18   EUBREAST e.V., Esslingen, Deutschland

  • A. Rody

    1   Universitätsklinikum Schleswig-Holstein Campus Lübeck, Lübeck, Deutschland

  • D. Langanke

    19   St. Elisabeth KH Leipzig-Brustzentrum, Leipzig, Deutschland

  • J. I. Sanchez Mendez

    20   Breast Unit – Hospital Universitario La Paz, Madrid, Spanien

  • V. Bjelic-Radisic

    21   Breast Unit, Helios University Hospital, Wuppertal, University Witten/Herdecke, Wuppertal, Deutschland

  • C. Solbach

    22   Breast Center, University Hospital, Goethe-University Frankfurt, Frankfurt, Deutschland

  • S. Cardenas Ovalle

    23   Ev. Waldkrankenhaus Spandau, Berlin, Deutschland

  • C. Mau

    8   Breast Cancer Center, Clinic for Gynecology and Obstetrics, Helios Klinikum Berlin-Buch, Berlin, Deutschland

  • N. Buchmann

    8   Breast Cancer Center, Clinic for Gynecology and Obstetrics, Helios Klinikum Berlin-Buch, Berlin, Deutschland

  • S. Riemer

    24   St. Joseph Stift Bremen, Bremen, Deutschland

  • M. H. Hansen

    25   University Hospital of North Norway, Tromsoe, Norwegen

  • L. Bauer

    26   GRN Klinikum Weinheim, Weinheim, Deutschland

  • J. Schnabel

    27   DRK Krankenhaus Chemnitz Rabenstein, Chemnitz, Deutschland

  • E. Von Abel

    28   Stauferklinikum Mutlangen, Mutlangen, Deutschland

  • N. Ditsch

    29   Breast Cancer Center, University Hospital Augsburg, Augsburg, Deutschland

  • T. Kühn

    30   Department of Gynecology and Obstetrics, Die Filderklinik, Filderstadt-Bonlanden, Deutschland
    31   Department of Gynecology and Obstetrics, University of Ulm, Ulm, Deutschland
Further Information
Also available at
 
 

Background: Axillary staging procedures in clinically node-positive (cN+) breast cancer patients undergoing neoadjuvant chemotherapy vary across countries. Different techniques are available for marking of target lymph nodes (TLN).

Methods: AXSANA is an international prospective study including cN+patients converting to ycN0 status. In this subgroup analysis, we focus on patients receiving a radar reflector marking of the target node.

Results: A TLN was marked using a radar reflector in 123 patients prior to neoadjuvant chemotherapy. Most patients (52%) had one suspicious node at time of diagnosis, followed by two (26%) and≥3 nodes (22%). 22 patients received MRI between marker placement and surgery and in 5 (23%) artifacts were visible. However, only in one (20%) of these patients, tumor assessment by MRI was limited by such artifacts. 81% of patients converted to ycN0.93 patients had undergone surgery at the time of analysis. Most patients (93%) received targeted axillary dissection, 3% underwent primary axillary dissection and 1% TLN biopsy. In 83 out of 85 patients (98%), the TLN was identified and removed. In one patient, no lymphatic tissue was identifiable in the tissue specimen containing radar reflector, so it remains unclear whether the TLN was excised or the reflector had dislocated. In another patient, the radar reflector was not identified intraoperatively but postoperative CT confirmed removal. Thus, no radar reflectors were left behind.

Conclusion: This is the largest prospective series of patients receiving a radar reflector for TLN marking prior to neoadjuvant chemotherapy, demonstrating very high detection and removal rates of TLN and marker.


Interessenskonflikt:

Ich erkläre als korrespondierende/r AutorIn, dass ich oder einer bzw. mehrere meiner Ko-AutorenInnen während der letzten 3 Jahre wirtschaftliche oder persönliche Verbindungen im oben genannten Sinne hatten: Interessenskonflikt Details: Maggie Banys-Paluchowski: Honorare für Vorträge und beratende Tätigkeiten: Roche, Novartis, Pfizer, pfm, Eli Lilly, Onkowissen, Seagen, AstraZeneca, Eisai, Amgen, Samsung, Canon, MSD, GSK, Daiichi Sankyo, Gilead, Sirius Medical, Syantra, resitu, Pierre Fabre, ExactSciences; Studienunterstützung: EndoMag, Mammotome, MeritMedical, Sirius Medical, Gilead, Hologic, ExactSciences; Erstattung von Reise- und Kongresskosten: Eli Lilly, ExactSciences, Pierre Fabre, Pfizer, Daiichi Sankyo, Roche. Keine weiteren COIs gemeldet.

Publication History

Article published online:
03 May 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany